Context: Catecholamine excess is rare, but symptoms may be life threatening.
Objective: The objective of the study was to investigate the sensitivity of 6-[F-18]fluoro-l-dihydroxyphenylalanine positron emission tomography ((18)F-DOPA PET), compared with (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy and computer tomography (CT)/magnetic resonance imaging (MRI) for tumor localization in patients with catecholamine excess.
Design And Setting: All consecutive patients with catecholamine excess visiting the University Medical Center Groningen, Groningen, The Netherlands, between March 2003 and January 2008 were eligible.
Patients: Forty-eight patients were included. The final diagnosis was pheochromocytoma in 40, adrenal hyperplasia in two, paraganglioma in two, ganglioneuroma in one, and unknown in three.
Main Outcome Measures: Sensitivities and discordancy between (18)F-DOPA PET, (123)I-MIBG, and CT or MRI were analyzed for individual patients and lesions. Metanephrines and 3-methoxytyramine in plasma and urine and uptake of (18)F-DOPA with PET were measured to determine the whole-body metabolic burden and correlated with biochemical tumor activity. The gold standard was a composite reference standard.
Results: (18)F-DOPA PET showed lesions in 43 patients, (123)I-MIBG in 31, and CT/MRI in 32. Patient-based sensitivity for (18)F-DOPA PET, (123)I-MIBG, and CT/MRI was 90, 65, and 67% (P < 0.01 for (18)F-DOPA PET vs. both (123)I-MIBG and CT/MRI, P = 1.0 (123)I-MIBG vs. CT/MRI). Lesion-based sensitivities were 73, 48, and 44% (P < 0.001 for (18)F-DOPA PET vs. both (123)I-MIBG and CT/MRI, P = 0.51 (123)I-MIBG vs. CT/MRI). The combination of (18)F-DOPA PET with CT/MRI was superior to (123)I-MIBG with CT/MRI (93 vs. 76%, P < 0.001). Whole-body metabolic burden measured with (18)F-DOPA PET correlated with plasma normetanephrine (r = 0.82), urinary normetanephrine (r = 0.84), and metanephrine (r = 0.57).
Conclusion: To localize tumors causing catecholamine excess, (18)F-DOPA PET is superior to (123)I-MIBG scintigraphy and CT/MRI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/jc.2009-1054 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment.
Front Endocrinol (Lausanne)
December 2024
One Health Research Group, Universidad de las Americas, Quito, Ecuador.
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors derived from chromaffin cells, with 80-85% originating in the adrenal medulla and 15-20% from extra-adrenal chromaffin tissues (paragangliomas). Approximately 30-40% of PPGLs have a hereditary component, making them one of the most genetically predisposed tumor types. Recent advances in genetic research have classified PPGLs into three molecular clusters: pseudohypoxia-related, kinase-signaling, and -signaling pathway variants.
View Article and Find Full Text PDFDeciphering F-DOPA uptake in SDH-related head and neck paragangliomas: a radiomics approach.
J Endocrinol Invest
December 2024
Nuclear Medicine and Molecular Imaging, ICANS, Strasbourg University Hospitals, Strasbourg University, Strasbourg, France.
Purpose: To investigate the influence of germline succinate dehydrogenase (SDHx) pathogenic variants on 6-[F]-fluoro-3,4-dihydroxyphenylalanine (F-DOPA) Positron Emission Tomography (PET) radiomic signature of head and neck paragangliomas (HNPGLs).
Methods: Forty-seven patients (20 SDH pathogenic variants carriers) harboring 55 HNPGLs were retrospectively included. HNPGLs were delineated using Nestle adaptive threshold.
Persistent hypoglycemia in congenital syphilis: hyperinsulinemic hypoglycemia with a focal pancreatic lesion.
J Pediatr Endocrinol Metab
November 2024
Department of Infectious Diseases, University of Health Sciences, Bursa Yuksek İhtisas Training and Research Hospital, Bursa, Türkiye.
Objectives: Congenital syphilis can cause severe morbidities such as hydrops fetalis, preterm birth, low birth weight, hepatosplenomegaly, pneumonia, hypoglycemia, etc., and mortality. Despite hypoglycemia being reported in congenital syphilis and hyperinsulinism, only one case was described.
View Article and Find Full Text PDF[Not Available].
Bull Cancer
October 2024
Service de médecine nucléaire et UCP thyroïde, Centre François-Badesse, 3, avenue du Général-Harris, 14000 Caen, France.
Article Synopsis
- Nuclear medicine continues to play a vital role in treating thyroid cancers, specifically through the use of iodine-131 (RAI) for differentiated thyroid cancer (DTC) and post-therapeutic scintigraphy to assess treatment response.
- For challenging cases where RAI isn't effective, FDG PET imaging aids in diagnosis and prognosis, particularly for less than 5% of those with refractory disease and for aggressive anaplastic thyroid cancer.
- Emerging theranostic strategies are being developed using various radiopharmaceuticals and imaging methods like 18F-DOPA, PSMA, and FAP, highlighting a shift from traditional treatments towards more personalized approaches in managing thyroid cancer.
[18F]DOPA PET for lesion definition and contouring using different thresholds in patients with gliomas.
Q J Nucl Med Mol Imaging
September 2024
Nuclear Medicine Unit, Department of Medical Sciences, AOU Città della Salute e della Scienza, Turin, Italy -
Article Synopsis
- The study examines the effectiveness of ESTRO-EANO guidelines for RT-planning in glioblastomas using [F]DOPA-PET, comparing their target definition thresholds (1.6-1.8) with traditional biological-tumor-volume (BTV) thresholds derived from the striatum. !* -
- An analysis of 50 glioma patients found that the striatum SUV
max threshold often resulted in smaller and less accurate tumor volumes, with significant discrepancies noted in many cases. !* - - The research concludes that the ESTRO-EANO thresholds for defining tumor volume are compatible with [F]DOPA-PET scans, while using the striatal SUV
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!